• Je něco špatně v tomto záznamu ?

Cooperation of germ line JAK2 mutations E846D and R1063H in hereditary erythrocytosis with megakaryocytic atypia

K. Kapralova, M. Horvathova, C. Pecquet, J. Fialova Kucerova, D. Pospisilova, E. Leroy, B. Kralova, JD. Milosevic Feenstra, F. Schischlik, R. Kralovics, SN. Constantinescu, V. Divoky,

. 2016 ; 128 (10) : 1418-23. [pub] 20160707

Jazyk angličtina Země Spojené státy americké

Typ dokumentu kazuistiky, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17031606

The role of somatic JAK2 mutations in clonal myeloproliferative neoplasms (MPNs) is well established. Recently, germ line JAK2 mutations were associated with polyclonal hereditary thrombocytosis and triple-negative MPNs. We studied a patient who inherited 2 heterozygous JAK2 mutations, E846D from the mother and R1063H from the father, and exhibited erythrocytosis and megakaryocytic atypia but normal platelet number. Culture of erythroid progenitors from the patient and his parents revealed hypersensitivity to erythropoietin (EPO). Using cellular models, we show that both E846D and R1063H variants lead to constitutive signaling (albeit much weaker than JAK2 V617F), and both weakly hyperactivate JAK2/STAT5 signaling only in the specific context of the EPO receptor (EPOR). JAK2 E846D exhibited slightly stronger effects than JAK2 R1063H and caused prolonged EPO-induced phosphorylation of JAK2/STAT5 via EPOR. We propose that JAK2 E846D predominantly contributes to erythrocytosis, but is not sufficient for the full pathological phenotype to develop. JAK2 R1063H, with very weak effect on JAK2/STAT5 signaling, is necessary to augment JAK2 activity caused by E846D above a threshold level leading to erythrocytosis with megakaryocyte abnormalities. Both mutations were detected in the germ line of rare polycythemia vera, as well as certain leukemia patients, suggesting that they might predispose to hematological malignancy.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17031606
003      
CZ-PrNML
005      
20171025123054.0
007      
ta
008      
171025s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1182/blood-2016-02-698951 $2 doi
035    __
$a (PubMed)27389715
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Kapralova, Katarina $u Department of Biology, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic; Signal Transduction and Molecular Hematology Unit, Ludwig Institute for Cancer Research, Brussels, Belgium; de Duve Institute, Université catholique de Louvain, Brussels, Belgium;
245    10
$a Cooperation of germ line JAK2 mutations E846D and R1063H in hereditary erythrocytosis with megakaryocytic atypia / $c K. Kapralova, M. Horvathova, C. Pecquet, J. Fialova Kucerova, D. Pospisilova, E. Leroy, B. Kralova, JD. Milosevic Feenstra, F. Schischlik, R. Kralovics, SN. Constantinescu, V. Divoky,
520    9_
$a The role of somatic JAK2 mutations in clonal myeloproliferative neoplasms (MPNs) is well established. Recently, germ line JAK2 mutations were associated with polyclonal hereditary thrombocytosis and triple-negative MPNs. We studied a patient who inherited 2 heterozygous JAK2 mutations, E846D from the mother and R1063H from the father, and exhibited erythrocytosis and megakaryocytic atypia but normal platelet number. Culture of erythroid progenitors from the patient and his parents revealed hypersensitivity to erythropoietin (EPO). Using cellular models, we show that both E846D and R1063H variants lead to constitutive signaling (albeit much weaker than JAK2 V617F), and both weakly hyperactivate JAK2/STAT5 signaling only in the specific context of the EPO receptor (EPOR). JAK2 E846D exhibited slightly stronger effects than JAK2 R1063H and caused prolonged EPO-induced phosphorylation of JAK2/STAT5 via EPOR. We propose that JAK2 E846D predominantly contributes to erythrocytosis, but is not sufficient for the full pathological phenotype to develop. JAK2 R1063H, with very weak effect on JAK2/STAT5 signaling, is necessary to augment JAK2 activity caused by E846D above a threshold level leading to erythrocytosis with megakaryocyte abnormalities. Both mutations were detected in the germ line of rare polycythemia vera, as well as certain leukemia patients, suggesting that they might predispose to hematological malignancy.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a zárodečné mutace $x genetika $7 D018095
650    _2
$a lidé $7 D006801
650    _2
$a Janus kinasa 2 $x genetika $7 D053614
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a megakaryocyty $x metabolismus $x patologie $7 D008533
650    _2
$a lidé středního věku $7 D008875
650    _2
$a fosforylace $7 D010766
650    _2
$a polycytemie $x vrozené $x genetika $7 D011086
650    _2
$a receptory erythropoetinu $x genetika $x metabolismus $7 D017467
650    _2
$a transkripční faktor STAT5 $x genetika $x metabolismus $7 D050799
650    _2
$a signální transdukce $7 D015398
650    _2
$a mladý dospělý $7 D055815
655    _2
$a kazuistiky $7 D002363
655    _2
$a časopisecké články $7 D016428
700    1_
$a Horvathova, Monika $u Department of Biology, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic;
700    1_
$a Pecquet, Christian $u Signal Transduction and Molecular Hematology Unit, Ludwig Institute for Cancer Research, Brussels, Belgium; de Duve Institute, Université catholique de Louvain, Brussels, Belgium;
700    1_
$a Fialova Kucerova, Jana $u Department of Biology, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic;
700    1_
$a Pospisilova, Dagmar $u Department of Pediatrics, University Hospital and Faculty of Medicine and Dentistry, Olomouc, Czech Republic; and.
700    1_
$a Leroy, Emilie $u Signal Transduction and Molecular Hematology Unit, Ludwig Institute for Cancer Research, Brussels, Belgium; de Duve Institute, Université catholique de Louvain, Brussels, Belgium;
700    1_
$a Kralova, Barbora $u Department of Biology, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic;
700    1_
$a Milosevic Feenstra, Jelena D $u CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
700    1_
$a Schischlik, Fiorella $u CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
700    1_
$a Kralovics, Robert $u CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
700    1_
$a Constantinescu, Stefan N $u Signal Transduction and Molecular Hematology Unit, Ludwig Institute for Cancer Research, Brussels, Belgium; de Duve Institute, Université catholique de Louvain, Brussels, Belgium;
700    1_
$a Divoky, Vladimir $u Department of Biology, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic;
773    0_
$w MED00000807 $t Blood $x 1528-0020 $g Roč. 128, č. 10 (2016), s. 1418-23
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27389715 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20171025 $b ABA008
991    __
$a 20171025123136 $b ABA008
999    __
$a ok $b bmc $g 1255199 $s 992633
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 128 $c 10 $d 1418-23 $e 20160707 $i 1528-0020 $m Blood $n Blood $x MED00000807
LZP    __
$a Pubmed-20171025

Najít záznam

Citační ukazatele

Možnosti archivace